Document is current

Any future updates will be listed below

Nivolumab in der Erstlinientherapie -gekommen, um zu bleiben?

Crossref DOI link: https://doi.org/10.1007/s15004-025-0919-8

Published Online: 2025-04-18

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark